- Home
- NUVL vs REYN Comparison
NUVL vs REYN Comparison
Compare NUVL & REYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- REYN
- Stock Information
- Founded
- NUVL 2017
- REYN 1947
- Country
- NUVL United States
- REYN United States
- Employees
- NUVL N/A
- REYN 6400
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- REYN Office Equipment/Supplies/Services
- Sector
- NUVL Health Care
- REYN Industrials
- Exchange
- NUVL Nasdaq
- REYN Nasdaq
- Market Cap
- NUVL 5.6B
- REYN 4.7B
- IPO Year
- NUVL 2021
- REYN 2020
- Fundamental
- Price
- NUVL $74.61
- REYN $22.08
- Analyst Decision
- NUVL Strong Buy
- REYN Buy
- Analyst Count
- NUVL 8
- REYN 9
- Target Price
- NUVL $115.50
- REYN $27.78
- AVG Volume (30 Days)
- NUVL 548.5K
- REYN 796.4K
- Earning Date
- NUVL 05-08-2025
- REYN 04-30-2025
- Dividend Yield
- NUVL N/A
- REYN 4.17%
- EPS Growth
- NUVL N/A
- REYN 1.25
- EPS
- NUVL N/A
- REYN 1.59
- Revenue
- NUVL N/A
- REYN $3,680,000,000.00
- Revenue This Year
- NUVL N/A
- REYN N/A
- Revenue Next Year
- NUVL N/A
- REYN $1.73
- P/E Ratio
- NUVL N/A
- REYN $13.89
- Revenue Growth
- NUVL N/A
- REYN N/A
- 52 Week Low
- NUVL $55.54
- REYN $21.63
- 52 Week High
- NUVL $113.51
- REYN $32.65
- Technical
- Relative Strength Index (RSI)
- NUVL 54.31
- REYN 39.64
- Support Level
- NUVL $70.25
- REYN $21.63
- Resistance Level
- NUVL $75.97
- REYN $22.43
- Average True Range (ATR)
- NUVL 3.09
- REYN 0.43
- MACD
- NUVL 0.13
- REYN -0.07
- Stochastic Oscillator
- NUVL 79.92
- REYN 21.28
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About REYN Reynolds Consumer Products Inc.
Reynolds Consumer Products Inc is a provider of household products. The firm is engaged in the production and sales of cooking products, waste and storage products, and tableware. It operates through four reportable segments namely, Reynolds Cooking and Baking, Hefty Waste and Storage, Hefty Tableware, and Presto Products. Reynolds Cooking and Baking segment produce branded and store brand aluminum foil, disposable aluminum pans, parchment paper, freezer paper, wax paper, butcher paper, plastic wrap, baking cups, oven bags and slow cooker liners.